Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

A user experienced significant hair regrowth using dutasteride without side effects, starting with finasteride and not using minoxidil or dermarolling. They attributed success to a unique genetic response to DHT blockers but did not share their full regimen, frustrating others.

A 17-year-old is using topical finasteride and minoxidil for hair regrowth. The effectiveness of these treatments is discussed, with some users noting progress and others suggesting more time is needed for significant results.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

A 17-year-old is experiencing genetic hair loss and is considering treatments like Minoxidil, Rosemary oil, or Finasteride. They have a vitamin D deficiency but believe it is not the cause of their hair loss.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation discusses hair regrowth progress using dutasteride 0.5 mg and oral minoxidil 2.5 mg over seven months. Users debate the effectiveness, with some noting slight improvements and others suggesting alternative treatments like finasteride.

Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A 17-year-old is using Finasteride and Minoxidil for hair loss, experiencing hair shedding and cystic acne. They are considering Dutasteride for acne but are concerned about potential side effects on genital development.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.